Investors focused on the Medical space have likely heard of ArQule , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ARQL and the rest of the Medical group's stocks.

ArQule is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ARQL is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for ARQL's full-year earnings has moved 18.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, ARQL has returned 215.76% so far this year. At the same time, Medical stocks have gained an average of 2.81%. This means that ArQule is performing better than its sector in terms of year-to-date returns.

Breaking things down more, ARQL is a member of the Medical - Drugs industry, which includes 163 individual companies and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 5.16% so far this year, meaning that ARQL is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on ARQL as it attempts to continue its solid performance.